The potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes
Research output: Contribution to journal › Journal article › Research › peer-review
In type 1 diabetes, average life expectancy is reduced by more than 10 years as compared with outside of diabetes. Residual cardiovascular risk defines high cardiovascular event rate despite modern, guideline-recommended standard of care of established risk factors like hypertension, dyslipidaemia, and glycaemic control, and it adds importantly to these lost years of life in type 1 diabetes due to atherosclerotic cardiovascular disease like myocardial infarction and ischaemic stroke. With growing understanding of inflammation as an important driver of atherosclerotic cardiovascular disease, residual inflammatory risk is a novel and common risk factor and a promising target for lowering residual cardiovascular risk in type 1 diabetes. Interestingly, the inexpensive anti-inflammatory agent colchicine reduced risk of major adverse cardiovascular events by 25% in cardiovascular outcome trials in the secondary prevention of atherosclerotic cardiovascular disease. Here, we summarise the role of inflammation as a driver of atherosclerosis and review current evidence linking inflammation and atherosclerotic cardiovascular disease in type 1 diabetes. Also, we provide an overview of the evidence base for targeting residual inflammatory risk with colchicine for lowering residual cardiovascular risk in type 1 diabetes.
Original language | English |
---|---|
Journal | European Heart Journal - Cardiovascular Pharmacotherapy |
Volume | 9 |
Issue number | 4 |
Pages (from-to) | 311-317 |
ISSN | 2055-6837 |
DOIs | |
Publication status | Published - 2023 |
Bibliographical note
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
ID: 339340466